Multivalent Glycoconjugates as Anti-Pathogenic Agents

A collective review article promoted by the European COST Action CM1102 (Multivalent Glycosystems for Nanoscience - MultiGlycoNano) provides an overview on the last advances of multivalent glycoconjugates that can be used to inhibit the adhesion of viruses, bacterial toxins, and bacteria to host cells or stimulate the immune system against these pathogens.

The authors : A. Bernardi, J. Jiménez-Barbero, A. Casnati, C. De Castro, T. Darbre, F. Fieschi, J. Finne, H. Funken, K-E Jaeger, M. Lahmann, T.K. Lindhorst, M. Marradi, P. Messner, A. Molinaro, P. V. Murphy, C. Nativi, S. Oscarson, S. Penadés, F. Peri, R.J. Pieters, O. Renaudet, J-L Reymond, B. Richichi, J. Rojo, F. Sansone, C. Schäffer, W. B. Turnbull, T.Velasco-Torrijos, S. Vidal, S. Vincent, T. Wennekes, H. Zuilhof and A. Imberty

Protein-glycan interactions are involved in the recognition between several pathogens and their hosts, including the first steps of infection and different stages of the immune response. The search for high-affinity ligands for studying such interactions comprises the multimerization of selected carbohydrates on different scaffolds in order to generate synthetic and multivalent glycoconjugates such as glycopolymers, glycodendrimers and glyconanoparticles.

The authors acknowledge the support from EU COST Actions CM1102 and COST BM1003. More information about the COST Action CM1102 can be found in the following web sites :